AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32408022 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver Support Intervention (CSI)
Number of subjects: 78
Study 32408022 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 78
Study 34125899 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose VitD/Ca supplementation (400 IU/1200 mg/day) for 48 weeks
Number of subjects: 200
Study 34125899 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose VitD/Ca supplementation (400 IU/1200 mg/day plus ergocalciferol 20,000 IU/week) for 48 weeks
Number of subjects: 200
Study 34125899 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups (Standard-dose and High-dose)
Number of subjects: 200
Study 33239945 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up at 80% VO2 max
Number of subjects: 9
Study 33239945 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up at 60% VO2 max
Number of subjects: 9
Study 33239945 — intervention group
Group type: COMPARATOR
Intervention: No warm-up (control)
Number of subjects: 9
Study 35751898 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen-Shugan (BSSG) method
Number of subjects: 100
Study 35751898 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 32991477 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback balance training with the Pro-kin system
Number of subjects: 40
Study 32991477 — intervention group
Group type: COMPARATOR
Intervention: Conventional balance training
Number of subjects: 40
Study 32991477 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-kin system parameters (perimeter and ellipse area)
Number of subjects: 40
Study 32991477 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed 'Up & Go' (TUG) test
Number of subjects: 40
Study 34389753 — intervention group
Group type: EXPERIMENTAL
Intervention: Orgono Powder (silicon as orthosilicic acid with maltodextrin)
Number of subjects: 5
Study 34389753 — intervention group
Group type: EXPERIMENTAL
Intervention: G5 Siliplant (silicon as orthosilicic acid with Equisetum arvense and Rosmarinus officinalis)
Number of subjects: 5
Study 34389753 — intervention group
Group type: EXPERIMENTAL
Intervention: G7 Aloe (silicon as orthosilicic acid with aloe vera)
Number of subjects: 5
Study 32026829 — intervention group
Group type: COMPARATOR
Intervention: Usual care: one usual physiotherapy advice and assessment session, including setting a physical activity goal and one follow up session (8 weeks).
Number of subjects: 41
Study 32026829 — intervention group
Group type: EXPERIMENTAL
Intervention: "Walk30×5": session one, usual care plus intervention of walking programme. Participants were shown the website and podcasts and practiced how to use them. One follow up session (8 weeks).
Number of subjects: 41
Study 36190944 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk modification (RM)
Number of subjects: 1557
Study 36190944 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure modification (EM)
Number of subjects: 1557
Study 36190944 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1557
Study 33624240 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobically digested swine manure at 25 g·kg‐1
Number of subjects: 3
Study 33624240 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobically digested swine manure at 10 g·kg‐1
Number of subjects: 3
Study 33624240 — intervention group
Group type: COMPARATOR
Intervention: Anaerobically digested swine manure at 0 g·kg‐1
Number of subjects: 3
Study 32338001 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-fried potato products (potato chips and French fries)
Number of subjects: 0
Study 32338001 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled potatoes
Number of subjects: 0
Study 32338001 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled rice
Number of subjects: 0
Study 34108431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (n = 10)
Number of subjects: 24
Study 34108431 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 24
Study 34859788 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg Mg as Mg citrate daily for 12 weeks
Number of subjects: 24
Study 34859788 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 12 weeks
Number of subjects: 24
Study 33254007 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness training
Number of subjects: 110
Study 33160891 — intervention group
Group type: EXPERIMENTAL
Intervention: LVGFI
Number of subjects: 129
Study 33160891 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct size
Number of subjects: 129
Study 33160891 — intervention group
Group type: EXPERIMENTAL
Intervention: Conicity index
Number of subjects: 129
Study 33160891 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphericity index
Number of subjects: 129
Study 36247849 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for tonifying kidney and removing blood stasis combined with radiofrequency surgery
Number of subjects: 122
Study 36247849 — intervention group
Group type: COMPARATOR
Intervention: CT-guided percutaneous radiofrequency ablation therapy
Number of subjects: 122
Study 36247849 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined detection of NTx, BGP, and CYFRA21-1
Number of subjects: 122
Study 32621106 — intervention group
Group type: EXPERIMENTAL
Intervention: ICCRTC classification system
Number of subjects: 60
Study 35241351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch adherence
Number of subjects: 70
Study 35241351 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal symptoms
Number of subjects: 70
Study 35241351 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of withdrawal symptoms
Number of subjects: 70
Study 35241351 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit day smoking status, patch adherence, duration of abstinence, and percent negative CO samples submitted
Number of subjects: 70
Study 36190380 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg per day for 12 weeks)
Number of subjects: 30
Study 36190380 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study 34291808 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioral Therapy for Insomnia (dCBT‐I)
Number of subjects: 101
Study 34291808 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face Cognitive Behavioral Therapy for Insomnia (FtF CBT‐I)
Number of subjects: 101
Study 32807435 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational support provided individually and in groups from the third to the eleventh day of hospitalization
Number of subjects: 78
Study 32807435 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 78
Study 35473459 — intervention group
Group type: EXPERIMENTAL
Intervention: Jcerity Endoscoper Airway (JEA)
Number of subjects: 182
Study 35473459 — intervention group
Group type: COMPARATOR
Intervention: LMA Supreme
Number of subjects: 182
Study 34972091 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour passive subdural drainage
Number of subjects: 420
Study 34972091 — intervention group
Group type: COMPARATOR
Intervention: 48-hour passive subdural drainage
Number of subjects: 420
Study 34193328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Therapy for Insomnia (MBTI)
Number of subjects: 127
Study 34193328 — intervention group
Group type: COMPARATOR
Intervention: Sleep Hygiene, Education, and Exercise Program (SHEEP)
Number of subjects: 127
Study 33678399 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-day Brush Day & Night programme
Number of subjects: 4125
Study 33678399 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4125
Study 32500957 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended hours dialysis (median 24 h/wk)
Number of subjects: 200
Study 32500957 — intervention group
Group type: COMPARATOR
Intervention: Standard hours dialysis (median 12 h/wk)
Number of subjects: 200
Study 33882590 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of aspirin
Number of subjects: 50
Study 35138715 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-at-home (HaH) care
Number of subjects: 0
Study 35138715 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 0
Study 32343001 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon Advance
Number of subjects: 26
Study 32343001 — intervention group
Group type: COMPARATOR
Intervention: Non-alginate antacid
Number of subjects: 26
Study 35195339 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + HMB
Number of subjects: 200
Study 35195339 — intervention group
Group type: EXPERIMENTAL
Intervention: RT
Number of subjects: 200
Study 35195339 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB
Number of subjects: 200
Study 35195339 — intervention group
Group type: COMPARATOR
Intervention: Negative Control
Number of subjects: 200
Study 35195339 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 200
Study 34428500 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct evidence from Randomized Controlled Trials (RCTs)
Number of subjects: 0
Study 34428500 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative approaches (non-randomized studies or RCTs on indirect populations)
Number of subjects: 0
Study 34326132 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg/day
Number of subjects: 151
Study 34326132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 36304748 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for CVDs in COPD patients based on predictors including gender, age, smoking history, BMI, history of blood transfusion, history of heart disease in close relatives, WBC, MONO, PLT, and LYM.
Number of subjects: 1022
Study 34921515 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracer contact
Number of subjects: 4380
Study 33577055 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg twice daily for 12 weeks)
Number of subjects: 22
Study 33577055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 32147280 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital aspiration
Number of subjects: 67
Study 32147280 — intervention group
Group type: COMPARATOR
Intervention: Manual aspiration
Number of subjects: 67
Study 36113275 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) combined with core stability-based balance training
Number of subjects: 30
Study 36113275 — intervention group
Group type: COMPARATOR
Intervention: Core stability-based balance training (Control group)
Number of subjects: 30
Study 34408055 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused brief therapy, up to six sessions over 3 months, offered immediately postrandomisation or after a delay of 6 months.
Number of subjects: 32
Study 34408055 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (delayed intervention).
Number of subjects: 32
Study 35507735 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-zone therapeutic concept (DZ)
Number of subjects: 24
Study 35507735 — intervention group
Group type: COMPARATOR
Intervention: Bone grafting to buccal bone crest (BCG)
Number of subjects: 24
Study 34505720 — intervention group
Group type: EXPERIMENTAL
Intervention: Income quartiles (highest income quartile)
Number of subjects: 2006
Study 34505720 — intervention group
Group type: EXPERIMENTAL
Intervention: Income quartiles (lowest income quartile)
Number of subjects: 2006
Study 34505720 — intervention group
Group type: COMPARATOR
Intervention: Income quartiles (all quartiles)
Number of subjects: 2006
Study 33153273 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial hardship treatment adherence
Number of subjects: 68
Study 33153273 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial stress
Number of subjects: 68
Study 33407146 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive predictive model using AST, anti-HBC, and GGT
Number of subjects: 577
Study 33407146 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver biopsy showing moderate or severe inflammation or significant fibrosis
Number of subjects: 577
Study 33407146 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors for antiviral therapy
Number of subjects: 577
Study 36007538 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 145
Study 36007538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 34340839 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 82
Study 34340839 — intervention group
Group type: COMPARATOR
Intervention: Standard multimodal analgesic regimen
Number of subjects: 82
Study 34709929 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax and obinutuzumab (Ven-Obi)
Number of subjects: 432
Study 34709929 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil and obinutuzumab (Clb-Obi)
Number of subjects: 432
Study 32580980 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive care protocol with structured individual visits (5 visits) with primary care nurse over 3 months
Number of subjects: 0
Study 32580980 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes care (comparison group)
Number of subjects: 0
Study 36098290 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational choir singing (RCS)
Number of subjects: 318
Study 36098290 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music therapy (GMT)
Number of subjects: 318
Study 36098290 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 318
Study 34735165 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocity strategy (delivery of inspirational quote prior to self-reporting)
Number of subjects: 68
Study 34735165 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmonetary reinforcers (e.g., delivery of meme/gif following self-reporting completion)
Number of subjects: 68
Study 34735165 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-reporting rates
Number of subjects: 68
Study 34363766 — intervention group
Group type: EXPERIMENTAL
Intervention: SafeCare programme (full package)
Number of subjects: 237
Study 34363766 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (control)
Number of subjects: 237
Study 32680754 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB combined with iPACK block and LFCNB (Group A)
Number of subjects: 200
Study 32680754 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB combined with iPACK block (Group B)
Number of subjects: 200
Study 32680754 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB combined with LFCNB (Group C)
Number of subjects: 200
Study 32680754 — intervention group
Group type: COMPARATOR
Intervention: ACB only (Group D)
Number of subjects: 200
Study 32680754 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 200
Study 36370991 — intervention group
Group type: COMPARATOR
Intervention: Psychological Intervention (PI) 2 times a week by a professional psychologist
Number of subjects: 49
Study 36370991 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Psychological Intervention (PI) and Electroacupuncture (EA) 30 min, 5 times a week for 4 weeks, total of 12 weeks
Number of subjects: 49
Study 35668502 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with Loss (LWL) program
Number of subjects: 150
Study 35668502 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 150
Study 32510111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (health risk assessment and nutrition counselling)
Number of subjects: 200
Study 32510111 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 200
Study 32510111 — intervention group
Group type: COMPARATOR
Intervention: Intervention group vs Control group
Number of subjects: 200
Study 34438002 — intervention group
Group type: EXPERIMENTAL
Intervention: Back rubs
Number of subjects: 186
Study 34438002 — intervention group
Group type: COMPARATOR
Intervention: Foot flicks
Number of subjects: 186
Study 35135601 — intervention group
Group type: EXPERIMENTAL
Intervention: Theraflu Daytime Severe Cold and Cough powder for oral solution
Number of subjects: 28
Study 35135601 — intervention group
Group type: COMPARATOR
Intervention: Theraflu ExpressMax Daytime Severe Cold and Cough caplet
Number of subjects: 28
Study 35816835 — intervention group
Group type: EXPERIMENTAL
Intervention: Information sharing between mental health service providers and criminal legal system stakeholders
Number of subjects: 35
Study 34591567 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships (PFR) program
Number of subjects: 252
Study 34591567 — intervention group
Group type: COMPARATOR
Intervention: Resource packet (control condition)
Number of subjects: 252
Study 32791893 — intervention group
Group type: EXPERIMENTAL
Intervention: Confiding in others
Number of subjects: 100000
Study 32791893 — intervention group
Group type: EXPERIMENTAL
Intervention: Television watching time
Number of subjects: 100000
Study 32791893 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime napping
Number of subjects: 100000
Study 616463935 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira in DUAL I
Number of subjects: 379
Study 616463935 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira in DUAL IV
Number of subjects: 379
Study 616463935 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira in DUAL II
Number of subjects: 379
Study 616463935 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec in DUAL I
Number of subjects: 379
Study 616463935 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide in DUAL I
Number of subjects: 379
Study 616463935 — intervention group
Group type: COMPARATOR
Intervention: Placebo in DUAL IV
Number of subjects: 379
Study 616463935 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec in DUAL II
Number of subjects: 379
Study 36316867 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic device (LSM-01)
Number of subjects: 30
Study 36316867 — intervention group
Group type: COMPARATOR
Intervention: Sham device (control)
Number of subjects: 30
Study 33080085 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride
Number of subjects: 17
Study 33080085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 35215453 — intervention group
Group type: EXPERIMENTAL
Intervention: ß‐glucan prebiotic
Number of subjects: 59
Study 35215453 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 33187850 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphenol A (BPA) exposure in groups B-D
Number of subjects: 80
Study 33187850 — intervention group
Group type: COMPARATOR
Intervention: Control group A (no BPA exposure)
Number of subjects: 80
Study 32145129 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid 5-10 mg
Number of subjects: 0
Study 32145129 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid 10 mg
Number of subjects: 0
Study 32145129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36479955 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy following CBT
Number of subjects: 139
Study 36479955 — intervention group
Group type: COMPARATOR
Intervention: No pharmacotherapy following CBT
Number of subjects: 139
Study 33508591 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine services
Number of subjects: 339
Study 33508591 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up
Number of subjects: 339
Study 35318844 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol intravenously, 500 mg once daily for 14 days, followed by oral Mexidol FORTE 250, 750 mg per day for 60 days
Number of subjects: 70
Study 35318844 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy only
Number of subjects: 70
Study 35318844 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol treatment
Number of subjects: 70
Study 34341325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 µg/kg for >10 min before anesthesia and during maintenance)
Number of subjects: 0
Study 34341325 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group, pumped for >10 min before anesthesia)
Number of subjects: 0
Study 36280032 — intervention group
Group type: EXPERIMENTAL
Intervention: REDEFINE program utilizing health promoters (HPs) performing spirometry in primary care clinics.
Number of subjects: 0
Study 36280032 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 33509489 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cue present with rice samples (0%, 0.05%, and 0.1% MSG concentrations)
Number of subjects: 151
Study 33509489 — intervention group
Group type: COMPARATOR
Intervention: Visual cue absent with rice samples (0%, 0.05%, and 0.1% MSG concentrations)
Number of subjects: 151
Study 35395938 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct diagnostic suggestion
Number of subjects: 44
Study 35395938 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorrect diagnostic suggestion
Number of subjects: 44
Study 35395938 — intervention group
Group type: COMPARATOR
Intervention: No diagnostic suggestion (control)
Number of subjects: 44
Study 33451618 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced counseling on optimal analgesic use
Number of subjects: 175
Study 33451618 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 175
Study 32468447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra Rapid Lispro (URLi)
Number of subjects: 80
Study 32468447 — intervention group
Group type: COMPARATOR
Intervention: Humalog (Lispro)
Number of subjects: 80
Study 32468447 — intervention group
Group type: EXPERIMENTAL
Intervention: URLi and Humalog
Number of subjects: 80
Study 36180905 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth swallowing therapy sessions
Number of subjects: 11
Study 34285177 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital sports vision training program
Number of subjects: 32
Study 34285177 — intervention group
Group type: COMPARATOR
Intervention: Placebo training procedures
Number of subjects: 32
Study 32789932 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with vicarious cancer experiences
Number of subjects: 207
Study 32789932 — intervention group
Group type: COMPARATOR
Intervention: Participants without vicarious cancer experiences
Number of subjects: 207